Leaflet VINBLASTINA TEVA 1mg / ml solution for injection

Indicated for: cancer

Route of administration: injectable

Substance: vinblastine (antineoplastic agent)

ATC: L01CA01 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Neuropathy / neurotoxicity
Neuropathy / neurotoxicity

This medicine may affect the nerves or nervous system.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Vinblastine is a chemotherapy medication used for the treatment of various types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, and breast cancer. It belongs to the vinca alkaloid class and works by inhibiting tubulin polymerization, leading to the arrest of cell division and tumor cell death.

Vinblastine is administered intravenously, usually once a week, and the dosage is adjusted based on body weight and patient response. Treatment is conducted under the supervision of an oncologist, and patients are monitored for signs of toxicity.

Common side effects include nausea, vomiting, hair loss, fatigue, and myelosuppression (reduction in blood cell counts). In rare cases, severe adverse reactions such as peripheral neuropathy or liver function impairment may occur.

Vinblastine is an important component of many chemotherapy regimens, helping to reduce tumor size and improve survival rates in cancer patients.

General data about VINBLASTINA TEVA 1mg / ml

  • Substance: vinblastine
  • Date of latest medicines list: 01-06-2026
  • Product code: W59211001
  • Concentration: 1mg / ml
  • Pharmaceutical form: solution for injection
  • Quantity: 1
  • Product type: Generic medicine
  • Price: 90.81 RON
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: PHARMACHEMIE B.V. - OLANDA
  • Holder: TEVA PHARMACEUTICALS S.R.L. - ROMANIA
  • Number: 13003/2020/01
  • Shelf life: 3 years- a se utiliza imediat dupa preparare

Pharmaceutical forms available for vinblastine

Concentrations available for vinblastine

  • 1mg/ml
  • 5mg

Compensation lists for VINBLASTINA TEVA 1mg / ml Teva

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

90.81 RON

90.81 RON

0.00 RON